Delving into the Latest Updates on Shanghai Huiyong Pharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Huiyong Pharmaceutical Co., Ltd., based in Shanghai, was established on May 10, 2018. The company is registered at the full building of 118 Meiyao Road, located within the China (Shanghai) Pilot Free Trade Zone.

Tags

Neoplasms

Nervous System Diseases

Digestive System Disorders

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1
Infectious Diseases	1

Top 5 Drug Type	Count

Chemical drugs	2
Small molecule drug	1

Top 5 Target	Count

HSPA5(78 kDa glucose-regulated protein)	1

主要目的：以药代动力学参数作为主要终点评价指标，分别比较在空腹/餐后状态下口服受试制剂美沙拉秦肠溶缓释颗粒（规格：1.5g，持证商：上海惠永制药有限公司）与参比制剂美沙拉秦肠溶缓释颗粒（规格：1.5g，持证商：Dr.Falk Pharma GmbH，商品名：Salofalk®）后在健康试验参与者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂美沙拉秦肠溶缓释颗粒和参比制剂美沙拉秦肠溶缓释颗粒在健康试验参与者中的安全性；评价受试制剂和参比制剂的适口性。

[Translation]

Primary Objective: To evaluate the bioequivalence of the test formulation mesalazine enteric-coated extended-release granules (1.5g, licensee: Shanghai Huiyong Pharmaceutical Co., Ltd.) and the reference formulation mesalazine enteric-coated extended-release granules (1.5g, licensee: Dr. Falk Pharma GmbH, trade name: Salofalk®) in healthy participants, using pharmacokinetic parameters as the primary endpoint. Secondary Objectives: To observe the safety of the test and reference formulations of mesalazine enteric-coated extended-release granules in healthy participants; to evaluate the palatability of the test and reference formulations.

Start Date03 Mar 2026

Sponsor / Collaborator

Shanghai Huiyong Pharmaceutical Co., Ltd.

CTR20253669

/ CompletedNot Applicable

盐酸坦索罗辛缓释胶囊在中国健康成年男性受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, two-period, two-sequence, single-dose, double-crossover bioequivalence study of tamsulosin hydrochloride extended-release capsules in Chinese healthy adult male subjects under fasting and fed conditions

主要目的：以药代动力学参数作为主要终点评价指标，分别比较在空腹 /餐后状态下口服受试制剂盐酸坦索罗辛缓释胶囊（规格：0.2mg，生产厂家：上海惠永制药有限公司）与参比制剂盐酸坦索罗辛缓释胶囊（规格：0.2mg，持证商：安斯泰来制药（中国）有限公司，商品名：哈乐®）后在健康研究参与者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂盐酸坦索罗辛缓释胶囊和参比制剂盐酸坦索罗辛缓释胶囊在健康研究参与者中的安全性。

[Translation]

Primary Objective: To compare the pharmacokinetic behavior of the test formulation, tamsulosin hydrochloride extended-release capsules (0.2 mg, manufacturer: Shanghai Huiyong Pharmaceutical Co., Ltd.), and the reference formulation, tamsulosin hydrochloride extended-release capsules (0.2 mg, licensee: Astellas Pharma (China) Co., Ltd., trade name: Harle®), in healthy study participants after oral administration in the fasting and fed states, using pharmacokinetic parameters as primary endpoints, and to evaluate the bioequivalence of the two formulations. Secondary Objective: To observe the safety of the test formulation, tamsulosin hydrochloride extended-release capsules, and the reference formulation, tamsulosin hydrochloride extended-release capsules, in healthy study participants.

Start Date10 Oct 2025

Sponsor / Collaborator

Shanghai Huiyong Pharmaceutical Co., Ltd.

CTR20252285

/ Active, not recruitingPhase 1

一项评价 LN016 缓释凝胶用于单侧开放性腹股沟疝修补术患者的安全性、耐受性、药代动力学及初步有效性的 I 期临床研究

[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of LN016 sustained-release gel in patients undergoing unilateral open inguinal hernia repair

主要研究目的: 评价在单侧开放性腹股沟疝修补术参与者中灌注 LN016 缓释凝胶的安全性和耐受性。次要研究目的: 评价在单侧开放性腹股沟疝修补术参与者中灌注LN016 缓释凝胶的药代动力学特征; 初步评价在单侧开放性腹股沟疝修补术参与者中灌注LN016 缓释凝胶的有效性。探索性研究目的: 评价在单侧开放性腹股沟疝修补术参与者中LN016 缓释凝胶的新辅料(EN001)的血浆和尿液中代谢物的药代力学特征。

[Translation]

Primary study objectives: To evaluate the safety and tolerability of LN016 extended-release gel infusion in participants with unilateral open inguinal hernia repair. Secondary study objectives: To evaluate the pharmacokinetic characteristics of LN016 extended-release gel infusion in participants with unilateral open inguinal hernia repair; To preliminarily evaluate the effectiveness of LN016 extended-release gel infusion in participants with unilateral open inguinal hernia repair. Exploratory study objectives: To evaluate the pharmacokinetic characteristics of metabolites of the new excipient (EN001) of LN016 extended-release gel in plasma and urine in participants with unilateral open inguinal hernia repair.

Start Date28 Jul 2025

Sponsor / Collaborator

Shanghai Huiyong Pharmaceutical Co., Ltd.

100 Clinical Results associated with Shanghai Huiyong Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Huiyong Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Huiyong Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Huiyong Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

2

1

Phase 2

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LN016	Analgesia More	Phase 2
LN005 ( HSPA5 )	Hepatocellular Carcinoma More	Phase 1
SN007	Anaerobic bacterial infection More	Phase 1
LN-006	Intestinal infections More	Pending